Mission

Various genetic and culture-based approaches are used for the surveillance of antimicrobial resistance (AMR). However, there are few harmonized, high-throughput platforms that target clinically relevant markers that indicate AMR mobility and multidrug resistance (MDR). In the TEXAS project, we will develop and validate two promising technological platforms addressing this gap. These technologies can be readily incorporated into national and international integrated surveillance programs.

Funding

The TEXAS project is enabled through national funding provided by the organizations participating in the JPIAMR 2023 call.

Logo by Eddie Cytryn